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In 1931 Frank used the term "premenstrual tension" 
to describe the fatigability, irritability, lack of con-
centration, and pain associated with the premenstrual 
phase of the female reproductive cycle. Generally, 
before and since this time variation in mood, especially. 
negative affect, was attributed to women because of the 
feminine cycle. The classic study of Benedek and Ruben-
stein (1939) first postulated the sexual cycle as a psy-
chosomatic unit, a physiological cycle with a psychodynamic 
response pattern. They, too, found increased depression 
and anxiety at the premenstruum, depression at the menses, 
and increased pleasant affect and sexuality at ovulation. 
Since then, research on the psychological aspects of 
menstruation has attempted to corroborate this psycho-
physiological formulation in relation to all women or 
specific personality types. 
Research into the physiological changes in women 
as a function of the menstrual cycle has also progressed. 
Recent studies indicate the important role of the cate-
cholamines, especially norepinephrine (NE), in the acti-
vation of the sexual cycle within the hypothalamic-
pituitary-ovarian system. 
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Also during the past two decades considerable 
data have accumulated in support of a catecholamine 
hypotheses of affective disorders. Simply stated, this 
hypothesis proposes that depressions are related to an 
absolute or relative decrease in catecholamines, 
especially NE, primarily in the central nervous system 
(CNS). Conversely, elation is related to an elevation of 
these catecholamines (Schildkraut, 1965). Three-methoxy-
4-hydroxyphenylglycol (MHPG), a major metabolite of brain 
NE is excreted in the urine, and correlations have been 
reported between urinary MHPG excretion and affect. In 
this disseration, the changes in anxiety and depression 
over the menstrual cycle as measured by self-report 
inventories will be studied in relation to MHPG levels 
as found in 24-hour urine collections of 11 women over 
an entire menstrual cycle. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
Physiology of the Menstrual Cycle 
To study fluctuations of mood as a function of 
the menstrual cycle, the hormonal changes which comprise 
the menstrual cycle must be documented. Recent research 
has divided the cycle into five phases: follicular, ovu-
latory, luteal, premenstrual, and menstrual (Moghissi, 
Syner, & Evans, 1972). 
The follicular phase lasts from the end of menses 
to a sharp rise in luteinizing hormone (LH). During this 
phase there is a gradual rise in estrogens, the major 
ones being estrone, estradiol, and estriol. The estrogen 
peak has been found to occur approximately one day before 
the LH peak (Abplanalp, Livingston, Rose, & Sandwisch, 
1977; Ribeiro, Mishell, & Thorneycroft, 1974). This 
estrogen peak stimulates LH from the pituitary gland. 
LH then induces ovulation. Simultaneously during the 
follicular phase, follicular stimulating hormone (FSH) 
stimulates the growth of follicles in the ovaries in 
preparation for ovulation. Levels of FSH begin with an 
early rise, a decline, and then a surge corresponding to 
the LH peak. 
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The ovulatory phase of the cycle is defined by 
the event of ovulation. Yen: Vela, Rankin, and Littell 
(1970) found LH peaks with an ascent of one to three 
days, followed by ovulation, and then an LH decline of 
one day. The lowest basal body temperature coincides 
with the first significant rise in LH levels. 
The luteal phase follows ovulation. With 48 
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hours after the LH peak, there is an elevated level of 
progesterone. This rise in progesterone is concomitant 
with a rise in basal body temperature (Yen et al., 1970). 
The LH, FSH, and the estrogens go to their lowest levels 
during the cycle other than the premenses. With the 
development of the corpus luteum, progesterone rises, 
peaking from five to eight days after the LH peak. Also 
there is a secondary rise in estrogens (Mishell, Nakamurra, 
Crosignani, Stone, Kharma, Nagata, & Thorneycroft, 1971). 
Basal body temperature is usually maintained above 98°F. 
Both estrogen and progesterone reach their nadir approxi-
mately two days before menstruation. This period is the 
premenstrual phase of the cycle. 
The menses occurs as a result of the withdrawal 
of stimulation by estrogen and progesterone to the edome-
trium. Bleeding usually occurs about 14-16 days after 
ovulation and lasts on an average of five days. The 
statistically average cycle is 28 days; yet few women have 
regular 28 day cycles. It is normal to have cycles as 
short as 20 days and as long as 45 (Weidiger, 1976). 
Figure 1 illustrates the hormonal changes throughout the 
cycle. 
This is a description of the phasic changes in 
the pituitary gonadotropins, LH and FSH, and the ovarian 
steroids, the estrogens and the progesterones. Recent 
studies suggest the neuroendocrine control of these 
cyclic hormone secretions in women. Figure 2 presents 
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a simple schematic representation based on the portal 
vessel chemotransmitter hypothesis of the relationship 
between the brain neurotransmitter systems, hypothalamic 
peptidergic neurons, the anterior pituitary, and the ovary. 
The hypothalamic peptidergic neurons, in this case those 
that release lutenizing hormone releasing factor (LHRF) 
are complexly influenced. The biogenic amines, dopamine 
(DA), Serotonin (5HT), acetylcholine (ACH), and NE act 
on LHRF in various combinations with either stimulatory 
or inhibitory effects. Also the peripheral hormones can 
bear on both the amines and the hypothalamic LHRF which 
further complicates the process. LHRF then enters the 
hypothalamohypophsialy portal system, is carried to the 
anterior pituitary, and influences the release of the 
pituitary gonadotropins, LH and FSH. LH then causes the 
synthesis of estrogen in the theca cells in the ovary. 
The ovary's secretion of steroids--the estrogens and 
Ovulation 







Figure l. Scheme relating plasma LH, FSH, estrogen, and 
progesterone with follicular maturation, ovulation, and develop-
ment of the corpus luteum. 
Note: Reproduced from (Strott, Yoshimi, Ross, & Lipsett, 1969, p. 1166) 
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Figure 2. Schematic representation of relationships between brain 
neurotransmitter systems, hypothalamic peptidergic (releasing factor) 
neurons, anterior pituitary, and peripheral endocrine organs 
illustrating established feedback loops. Dopamine, OA; norepine-
phrine, NE: serotonin, 5HT; acetylcholine, ACh; thyrotropin-releasing 
factor, TRF; luteinizing hormone releasing-factor, LHRF; somatostatin, 
SRIF; melanocyte-stimulating hormone release-inhibiting factor, MIF; 
corticotropin-releasing hormone, CRF; prolactin-inhibiting factor, 
PIF; thyroid-stimulating hormone, TSH; luteinizing hormone, LH; 
follicle-stimulating hormone, FSH; prolactin, PRL; growth hormone, 
GH; and adrenocorticotrophic hormone, ACTH. 
Note: Reproduced from (Nemeroff & Prange, 1978, p. 1004) 
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possibly progesterone and androgen--may feedback at three 
levels and the pituitary hormone, LH and FSH, at two 
levels. For example, estrogen may modulate LH and FSH in 
the pituitary. Estrogens may also penetrate the brain and 
influence the monamines. Another feedback loop may involve 
LH traveling back to the hypothalamus {Nemeroff & Prange, 
1978). 
Yen {1977) discussed the hypotheses explaining the 
LH surge which then triggers ovulation. Among them, he 
mentioned the role of progesterone in stimulating LH at 
midcycle when estrogen levels are high. The increase in 
estrogen at midcycle may increase the relative neuronal 
release of NE and DA which in turn increases the release 
of LHRF. Progesterone may enhance this effect. 
Experiments with animals have tested the role of 
brain catecholamines in influencing ovulation. Rubinstein 
and Sawyer {1970) tested whether depletion of hypothalamic 
catecholamines affected the stimulation of ovulation in 
proestrus rats. Partial and total depletions of cate-
cholamines were created from timed injections of reserpine 
and monamine oxidase (MAO) inhibitors. Short term treat-
ment with reserpine blocked spontaneous ovulation and 
elevated the threshold for electrically stimulated ovula-
tion. After longer reserpine action which depleted 
catecholamine pools, MAO inhibitors restored enough 
catecholamine to allow stimulated but not spontaneous 
ovulation. Injection of epinephrine (E) into the third 
ventricle was found the most effective catecholamine in 
triggering ovulation. 
Sawyer, Hilliard, Kanematsu, Scaramuzzi, and 
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Blake (1974) report that a 50 microgram (~g) intraven-
tricular dosage of NE was completely effective in inducing 
a surge of LH which resulted in ovulation in estrogen-
primed rats. A 50 ~g dosage of DA did not trigger the 
surge in fact acted as an inhibitor when NE was injected 
one to two weeks after DA. This contradicts other research 
which found that DA was effective in stimulating ovulation 
(Kamberi, Mical, & Porter, 1970; Schneider & McCann, 
1970). 
Kalra, Kalra, Krulich, Fawcett, and McCann (1972) 
found that injections of progesterone into estrogen-primed 
rats resulted in an LH and FSH surge. They wished to test 
whether adrenergic blockers would affect these LH and FSH 
surges. Drugs used to modify brain catecholamines were 
injected prior to the progesterone administration. Both 
the DAand NE blockade prevented the release of gonado-
tropins; however, when DA was normalized and NE levels 
remained low, the blockade of progesterone induced LH 
release remained effective. The authors concluded that NE 
mediates progesterone-induced release of the gonadotropins 
necessary for ovulation. 
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Kalra and McCann (1973) found that the stimulation 
of the preoptic region or the median eminence-arcuate 
region of the brain in proestrus rats led to elevation of 
plasma LH. Blockade of catecholamines or NE alone made 
stimulation of the preoptic region ineffectual in 
increasing LH levels. Taken with their other research, the 
authors conclude that NE acts as a synaptic transmitter 
in the preoptic-tuberal pathway leading to the release of 
LH necessary for ovulation. 
The hypothesis advocating the necessary activity 
of the monoamines in the female sexual cycle was tested 
in the above studies with the administration of various 
drugs which manipulate levels of brain monoamines. Other 
studies with animals have measured monoamines and related 
enzymes and metabolites to discover fluctuating levels 
of amine activity during the menstrual cycle. 
Measurement of monoamine activity is often indirect. 
A frequent method of measurement is the estimation of MAO, 
a major enzyme in the catabolism of brain catecholamines. 
Based on the relief of depression by MAO inhibitors, it 
is assumed that increased MAO activity is related to 
depression and low NE levels. 
Zolovick, Pearse, Boehlke, and Eleftheriou 
(1966) estimated the activity of MAO in the hypothalamus, 
amygdala, and frontal cortex of the brain during the estrus 
cycle of female rats. The MAO activity was lowest at 
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diestrus in all three areas and highest at proestrus when 
follicular action is heightened. The hypothalamus evi-
denced the greatest amount of activity throughout the 
cycle. Actual brain tissue was analyzed for these results. 
Platelet MAO, which is similar to MAO in the brain, 
has been studied in relation to the menstrual cycle. 
Redmond, Murphy, Baulu, Ziegler, and Lake (1975) found 
a significant difference between a mid-cycle peak in 
platelet MAO and a premenstrual low point during three 
cycles of six female rhesus monkeys. Also ovariectemized 
monkeys showed higher MAO levels than controls. The 
authors conjecture that peak platelet MAO activity might 
be time-lagged and actually correlated with low estrogen 
levels which occur within ten days before the estrogen 
peak prior to ovulation. 
Using human subjects, Belmaker, Murphy, Wyatt, 
and Loriaux (1974) also found peak platelet MAO activity 
during the ovulatory phase and lowest values occurring 
five to eleven days later. These studies suggest that 
increased MAO activity is related to an increase in 
estrogen. 
In contrast, other studies associate low MAO 
activity with high estrogen levels. Klaiber, Kobayashi, 
Braverman, and Hall (1971) found that plasma MAO activity 
was significantly lower during the ovulatory phase when 
estrogen was high than postovulatory when progesterone 
12 
was highest. Also amenorrheic and postmenopausal women 
had higher levels of MAO than menstruating women at pre-
ovulation. Their MAO levels went down when given estrogen 
therapy while addition of progesterone increased the MAO 
activity over that observed during estrogen therapy alone. 
Also Briggs and Briggs (1972) found plasma MAO activity 
in women at midcycle to be significantly lower than that 
of male controls. During the luteal phase, the men and 
women were not different. Southgate, Grant, Pollard, 
Pryse-Davies, and Sandler (1968) found an increase in 
endometrial MAO during the late luteal to premenstrual 
phases. Histochemical and biochemical assays of biopsy 
tissue were examined in their study. Furthermore, Grant 
and Pryse-Davis (1968) studied the effect of oral contra-
ceptives on endometrial MAO and depressive mood. The 
highest incidence of depression was associated with pro-
gesterone compounds which produced high MAO activity 
throughout the cycle. The lowest occurrence of depression 
was found in women treated with highly estrogenic sequen-
tial contraceptives which showed weak MAO activity during 
the cycle. Finally, Robinson, Davis, Nies, Ravaris, 
Sylwester, and Burlington (1971) found MAO activity from 
biopsies of the hindbrain of 26 autopsies and plasma and 
platelet MAO assayed in 113 normal subjects to be highly 
correlated with increasing age. Depressive illness is 
also correlated with increasing age and loss of estrogen 
in women. These studies seem to indicate that the 
estrogen increase at midcycle is associated with lower 
MAO activity which in turn may reflect elevated 
catecholamine levels and therefore elevation in mood. 
Direct measurement of NE during the female men-
strual cycle has been undertaken. Zuspan and Zuspan 
(1973) investigated the theory that NE was involved in 
the control of gonadotropin secretion during the human 
menstrual cycle. They studied two normally cycling 
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women for a complete menstrual cycle with blood determin-
ations of LH, FSH, E, and NE and urinary determinations 
of creatinine, NE, and E. Both subjects showed a signi-
ficant increase in plasma amines coincidental with or 
preceding the LH surge before ovulation. They also showed 
a gradual rise in urinary NE after ovulation which was 
greater than preovulatory levels. Rosner, Nagle, 
delaBorde, Pedroza, Badano, Figuero, Casas, and Carril 
(1976) found that plasma NE peaked one day prior to con-
comitant with the LH peak. Plasma estradiol also reached 
a peak on the day of the LH peak. 
In another phase of their work, a single intra-
venous 100 ~g dose of LHRF was administered to four sub-
jects on day ten of the cycle. A significant rise in 
plasma NE was found occurring before an LH surge. Zacur, 
Tyson, Ziegler, and Lake (1978) failed to corroborate this 
relationship between NE and the pituitary gonadoptopin LH. 
Also, Patkai, Johannson, and Post (1974) found no cyclic 
changes in urinary NE. However, they had divided the 
cycle into equal segments. 
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Badano, Nagle, Casas, Miechi, Murkin, Turner, 
Aparicio, and Rosner (1978) investigated the plasma levels 
of NE in 11 free-cycling women. Blood samples were taken 
daily from day -8 to -4 and every eight hours from day 
-3 to +2. Ovulation, determined during surgery for 
benign gynecologic problems, was designated as day 0. 
In nine ovulatory patients, estradiol levels peaked 48 
hours before the LH peak. The NE was at low levels until 
eight hours after the estradiol peak when NE increased 
significantly. The NE fell again in the next eight hours 
and rose again reaching maximal levels 24 hours after the 
estradiol peak. Sixteen hours before the LH peak, NE 
gradually declined. Two anovulatory women showed atypical 
patterns of estradiol, progesterone, NE, and LH. The NE 
showed much variation without correlation with the 
estradiol or LH. This study supports previous research 
with women and animals that NE and possibly other catecho-
lamines may act as a triggering mechanism to ovulation. 
It also indicates that contradictory results in MAO and 
NE measurement during the menstrual cycle may depend on 
the time of measurement. Catecholamine levels appear to 
change rapidly at the time of ovulation. 
The studies cited above report fluctations over 
the cycle from both brain and peripheral catecholamine 
pools. Animal research cited indicates the activation 
of NE and MAO in the brain. Research on humans has 
analyzed urinary, plasma, and platelet levels. Whether 
these levels of MAO and NE in humans are from CNS or 
peripheral sources is unclear. 
Psychological Variation During 
the Menstrual Cycle 
The earliest studies on the variations of mood 
during the menstrual cycle include that by Frank {1931) 
who used the term 11 premenstrua1 tension 11 to label the 
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weight gain, irritability, fatigability, and lack of con-
centration associated with the premenstrual and menstrual 
phases of the female reproductive cycle. He described 
women who suffered such severe pain that they required 
bedrest. Another group were those who show exacerbation 
of general disorders such as asthma prior to menstruating. 
He was at the time reporting methods of treatment for 
severe symptoms. His research is one of the first publi-
cations to designate a premenstrual syndrome. 
By 1939, the use of vaginal smears and basal body 
temperature to determine the hormonal cycle had been 
established. Therefore, Benedek and Rubenstein (1939, 
Part I and II) studied the correlations between the physio-
logical factors and the psychological factors. They used 
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vaginal smears, temperature charts, and the associative 
material from nine analytic patients. Seventy-five cycles 
of which 23 were ovulatory were studied. The authors 
investigated primarily the associations, the dreams, and 
the transference. They noted that at the follucular phase 
where estrogen is the predominating hormone, the psycho-
logical material of the women dealt with heterosexual 
tendencies; the dominant feelings were of well-being and 
alertness. If there was no opportunity for gratification 
for libidinal urges, the mood of the women was irritable 
and restless. The psychological content within a 
Freudian model was then characterized by aggression and 
anxiety, i.e., fear of attack, penis envy, and intense 
wishes to castrate. Of course, since the majority of the 
subjects were characterized as neurotic in this study, 
most of them did not attain sexual gratification. Tension 
or depression increased as ovulation approached. At 
ovulation, relaxation and an attitude of passivity along 
with psychic energy directed toward the self generally 
occurred in the women. During the early luteal phase, 
under the influence of progesterone, the dream content 
reflected mother-daughter conflicts and then concerns 
about impregnation and motherhood. 
When there was another estrogen peak during the 
luteal phase, heterosexual fantasies were again present as 
during the follicular phase. This was a relatively quiet 
phase of affect. During the premenstrual phase, when 
there was a drop in the level of progesterone and 
estrogen, dream content and the associations of the 
women reflected elimination tendencies illustrated on a 
genital level by childbirth, abortion, castration and on 
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a pregenital level as anal or uretheral discharge. The 
emotions were characterized by fear of pain and mutilation 
and by feelings of regret and inadequacy. At menses, with 
low hormone production, there was emotional relaxation; 
fear, apprehension, and rebellion decreased. Conclusions 
made by Benedek and Rubenstein (1939, Part II) were as 
follows: (1) correlations were seen between the physio-
logical and psychological cycle; (2) instinctual drives 
of adult women are related to hormone production; 
(3) instinctual tendencies are genital when hormone pro-
duction is high and pregenital when they are low; and 
(4) psychic tension often increases with an increase in 
hormone production. 
In contrast to the work of Benedek and Rubenstein 
(1939) who studied the repressed sexual drive of neurotic 
women as correlated with the phases of the cycle, Altman, 
Knowles, and Bull (1939) studied the conscious mental 
states of ten normal women. They took daily psychological 
measures and interviewed each subject daily as to pain, 
sleep, mood, tension, worry, physical and mental activity. 
They reported the following findings: (a) ovulation 
occurred with elation in 67.8% of cases, with activity 
in 85.3% and with tension in 31.4%; and (b) the pre-
menstrual phase occurred with depression in 61.5%, with 
activity in 71.8%, and with tension in 80% of cases. 
Many correlational studies have drawn attention 
to the increase of negative affect at the premenstruum 
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and menstruum. They have attempted to correlate extra-
ordinary events such as crime or suicide with the premen-
strual or menstrual phases. Dalton summarized much of 
this work and has been a leading contributer of this type 
of research. Dalton (1961) reported that in a sample of 
156 newly convicted female prisoners, 49% committed their 
crimes during the menstruum or premenstruum. Among 51 
prisoners who were reported for disorderly conduct, 54% 
were menstruating. In this study Dalton divided the cycle 
with days one to four in menstruation, 13-16 in ovulation, 
and 25-28 in premenstruum. Dalton (1961) corroborated 
Dalton's work with school girls (Dalton, 1960). She 
found 27% of the girls' weekly grades went down during 
premenstruum and 17% went up; 25% went down during the 
menstrual week and 30% went up after menstruation. In 
this study she divided the cycle into four weeks. She 
then concentrated on the menstrual and premenstrual weeks 
(Dalton, 1960). 
Exacerbation of psychiatric symptoms in relation 
to the menstrual cycle has been studied frequently. One 
19 
study (Glass, Heninger, Lansky, & Tolan, 1971) evaluated 
166 female psychiatric emergencies. These patients were 
seen in the emergency room during the premenstruum twice 
the expected frequency. A certain type of woman presented 
herself during the premenstrual weeks. She was a non-
psychotic woman who had a severe history of medical ill-
ness, past marital and sexual problems and a record of 
suicidal attempts. Jacobs and Charles (1970) similarly 
studied 200 randomly selected patients coming into an 
emergency room. They used Dalton's method defining mid-
cycle as the 13-16 days and 25-28 days as premenstruum. 
The women sought psychiatric help most frequently during 
menstruation (24.5%), then during the premenstrual phase 
(22.5%), and finally during midcycle (18%). There was no 
clear difference between the menstrual and premenstrual 
phases. Diamond, Rubenstein, Dunner, and Fieree (1976) 
also found that psychiatric hospitalization occurred sig-
nificantly more frequently during the menstrual and the 
premenstrual phase. 
Tonks, Rack, and Rose (1967) obtained information 
on 95 women who attempted suicide. A statistically signi-
ficant increase iri attempts was found at the premenstruum. 
The trend was found primarily in women living with a male. 
Fewest premenstrual attempts were made by parous women who 
complained of premenstrual tension. 
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Dalton's (1959) findings that more hospital 
admissions for suicide attempts occurred during the 
menses than other phases have been criticized since the 
psychiatric admissions were actually premenstrual rather 
than menstrual because of the lag in hospital admissions. 
Mandell and Mandell (1967) wanted to corroborate the 
findings ofDalton. They described 87 menstruating women 
who called a suicide prevention center. Highest number 
of calls were found the first day of menstruation, second 
highest were found during the premenstruum, and third 
highest at midcycle. Ribeiro (1960) reported 22 cases of 
suicide by Hindu women, 19 of whom were menstruating. 
Other recent studies can be divided according to 
the methodology employed: (1) those studies using retro-
spective reports; (2) those studies using single measures 
from various phases of the cycle; and (3) those studies 
using daily self-reports. In the first category of 
retrospective reports, Coppen and Kessel (1963) sent out 
a menstrual questionnaire to 500 women, ranging in age 
from 18 to 25. Twenty-two percent were menstruating at 
the time of completing the form. This group did not 
differ from the nonmenstruating group in severity of 
symptoms. The form asked the women whether they became 
depressed, anxious or nervous around the time of their 
period. Irritability, depression, tension, headache, and 
swelling occurred most frequently one or more days before 
menses. One woman in nine reported severe pain, irri-
tability or headaches associated with her period. One 
woman in 16 reported that she gets depressed or tense. 
Statistical analyses, however, were not employed to 
clarify these findings. 
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Lamb, Ulett, Masters, and Robinson (1953) also 
conducted a survey of 127 nurses with a mean age of 20.3. 
Of these, 28% reported some dysmenorrhea sometimes; 50% 
had it always. Depression, irritability, temper outbursts 
occurred at premenses singly or together in 85% of the 
subjects. This type of retrospective survey is suspect, 
however, because of possible faulty memory, the mood when 
taking the test, and the popular belief that poor mood 
results from "getting your period." 
The second category of studies, those taking a 
single measure of affect at a different phase of the cycle 
further corroborate the existence of heightened negative 
affect during the premenses and menses. Lamb et al., 
(1953) compared five women who complained of the premen-
strual syndrome and five who did not. The authors con-
ducted interviews at the time of ovulation, premenses, 
and onset of menstruation. Then each subject was rated 
on mood, activity level, and assertiveness. They found 
that at the premenstruum those who complained of premen-
strual tension became depressed and were either hypo-
or hyperactive, whereas controls were not. Premenstrual 
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complainers also tended to be more hostile and aggressive 
than the controls whereas at other times of the cycle 
they were more submissive. 
Ivey and Bardwick (1968) tested anxiety levels 
of college women ages 19 to 22. The women were told they 
were cooperating in a study on the menstrual cycle and 
that they would be tested at ovulation and premenses. They 
were asked to talk for five minutes about any event in 
their lives. This verbal sample was then scored accord-
ing to Gottschalk's {1961) Verbal Anxiety scale for death, 
mutilation, separation, guilt, shame, and diffuse anxiety. 
Anxiety levels were significantly higher premenstrually 
than at ovulation for all subjects for two complete cycles. 
Also they found consistent themes of hostility and 
depression and inability to cope at the premenses. Atten-
tion must be paid to the fact that the subjects knew the 
times of the cycle at which they were being tested. To 
evaluate the impact of this confound, the authors asked 
the women what they guessed was the purpose of the study. 
The authors claim none of the women suspected their moods 
were being assessed. 
Luschen and Pierce (1972) studied 48 women from 
ages 18 to 22, having 24 subjects in a premenstrual group 
and 34 in an ovulatory group. Ovulation was defined as 
15 days prior to the next expected menses. Despite the 
fact that the 15th day prior to menses is not always the 
day of ovulation, differences were found. The ovulatory 
group was significantly more other-directed than the 
premenstrual group. Also women at ovulation had higher 
sexual arousability scores than those at premenses. One 
possible confound in this study was that birth control 
pill takers were in the groups. The authors claimed 
that their scores did not differ from those of the free-
cycling women. 
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To investigate the changes in symptoms and affect 
overtwo consecutive cycles, Moos, Kopell, Melges, Yalom, 
Lunde, Clayton, and Hamburg (1969) tested a group of 15 
women on the 2nd, 7th, 14th, 19th, 24th, 25th, 26th, 27th, 
and 28th days. Mood was measured by the Nowlis Mood 
Adjective Checklist (1965). Results show pain and water 
retention highest at menses, dropping to the lowest point 
during the follicular phase, and rising again after the 
16th day. Anxiety was highest during the menstrual 
phase and dropped at midcycle, then began to rise during 
the luteal phase. Pleasant affect and activation peaked 
at midcycle and were lowest at menstruation. Sexual 
arousal also peaked at midcycle. Surprisingly, depression 
showed no noticeable changes over the cycle. Correlations 
between the two cycles were generally high at the 
menstrual, intermenstrual and premenstrual phases. 
Although phase changes were not analyzed statistically, 
this study does show fluctuations in mood over a cycle 
which seems to be fairly consistent from cycle to cycle. 
The work of Paige (1971) showed increase in 
negative affect at the time of premenses and menses. In 
this study, free-cycling women were compared to women on 
combination contraceptives and women on sequential con-
traceptives. They were measured on the 4th, lOth) 16th, 
and 26th days with the Gottschalk Verbal Anxiety Scale 
(1961). Total negative affect for all the groups across 
the cycle was not different. Cycle day for the normal 
group had a significant effect on the magnitude of nega-
tive affect, anxiety and hostility. Free-cycling women 
showed the usual U-shaped curve of high negative affect 
at menses, low at midcycle and high at premenses. 
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Golub (1976) assessed the magnitude of depression 
and anxiety in women between the ages of 30 and 45 who 
were described as "active women leading productive lives" 
(p. 10). She used the Lubin (1967) Depression Adjective 
Checklist (DACL) and the Spielberger, Gorsuch, and 
Lushene (1970) State-Trait Anxiety Inventory (STAI). 
About 75% had higher premenstrual depression and about 
65% had higher premenstrual anxiety than intermenstrual 
depression and anxiety. The mean scores were signifi-
cantly higher at premenses than intermenses. In comparing 
premenstrual to intermenstrual, however, the information 
culled was unspecific since 11 intermenstrual 11 could 
refer to follicular, periovulatory or luteal phases, 
all having different hormone balances. 
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Abplanalp et al. (1977) administered the state-
anxiety form of the STAI before and after a mildly 
stressful interview. Half the subjects were interviewed 
during their menses and the other half during the peri-
ovulatory phase. The time of ovulation, however, was 
correctly estimated only in about 59% of the cases when 
compared with the results of the biochemical analyses. 
State-anxiety differences between pre and post interview 
were not significant despite phase of the cycle at which 
the subject was interviewed. Where Golub (1976) found 
significant changes in anxiety between the premenstruum 
and intermenstruum, Abplanalp et al. (1977) found no 
variation in state-anxiety between the menstrual and 
intermenstrual phases. In general, the research cited 
above, using a single measurement per phase, is conflict-
ing yet does indicate that there is a fluctuation of mood 
with negative affect high at menses, low at ovulation, 
and high again at premenses. Only in Ivey and Bardwick 
(1968) was there an attempt to establish ovulation by 
basal body temperature. Therefore although changes in 
mood are found, the precise nature of the changes as they 
relate to hormonal changes is not clear. 
Other studies collected daily self-reports. 
Silbergeld, Brast, and Noble (1971) had eight subjects, 
four who were first on Enovid for two cycles, then were 
freecycling for two cycles, and four subjects who were 
reversed. Each night subjects rated their feelings on 
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the Nowlis Adjective Checklist (1965) and the Moos (1977) 
Menstrual Distress Questionnaire (MDQ). On nine days 
throughout the cycle, they were scored on the Gottschalk 
Verbal Anxiety Scale (1961) based on talking freely for 
five minutes. The data were divided into six phases: 
menstrual, midfollicular, early ovulatory, late ovulatory, 
midluteal and premenstrual. Only for anxiety rated by an 
unaware experimenter was there a significant treatment 
by phase interaction. Analysis for phase effects showed 
an increase in physical symptoms at the menstrual and 
premenstrual phases. The women reported more crying, 
irritability, and tension and were rated more tense and 
aggressive during the premenstrual phase than during the 
other phases. 
Wilcoxon, Schrader, and Sherif (1976) took daily 
self-reports. Their subjects, from an introductory 
psychology course, were 11 males, 11 females/no pill, 
and 11 females/pill. They divided the cycle into three 
phases: intermenstrual, premenstrual, and menstrual. 
Sample by phase interactions were significant. Females/no 
pill peaked on negative affect at menses while females/pill 
peaked premenstrually. Impairment of concentration and 
report of stressful events increased premenstrually for 
both groups and decreased menstrually for females/pill. 
Stressful events, however, accounted for more of the 
variance for negative affect than cycle phase. The 
authors also noted that caution be used in interpreting 
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the data because on all 13 factors they measured, subjects• 
variance, amount of individual difference, contributed 
more to the variance than sample, cycle phase, or inter-
action of sample and cycle although all these were signi-
ficant. 
The psychological literature on the menstrual 
cycle shows many methodological problems such as (l) the 
absence of exact determination of ovulation, (2) the 
possible confound by cultural stereotypy concerning 
menstruation, and (3) the large amount of individual 
variation of women during their menstrual cycles. Yet 
the trend seems to indicate the existence of an increase 
in irritability, tensinn, and depression at the onset of 
menstruation. Also midcycle, or the ovulatory phase, 
is a time of fewer symptoms. 
MHPG and the Catecholamine Hypothesis 
of Affective Disorder 
These fluctuations in affect are often attributed 
to biochemical changes occurring during the menstrual cycle. 
Also changes in affect have been related to changes in 
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brain catecholamines. According to Schildkraut (1965, 
p. 509), the 11 Catecholamine hypothesis of affective dis-
orders proposes that some if not all depressions are asso-
ciated with an absolute or relative decrease in catechola-
mines, particularly NE, available at central adrenergic 
receptor sites. Elation, conversely, may be associated 
with an excess of such amines. 11 He reviewed pharmacologi-
cal studies of antidepressant drugs which indicated the 
effects of these drugs on catecholamines. The MAO inhi-
bitors increase brain NE by direct inhibition of the enzyme 
MAO which deaminates NE. Imiprimine-like drugs increase 
free NE by inhibiting neuronal reuptake. Reserpine, a 
drug which causes depression, depletes catecholamines by 
interfering with storage in the neuron. The catecholamine 
hypothesis has been inferred from drug studies but these 
are indirect ways of measuring catecholamines. Direct 
measurement of NE and other catecholamines is complicated 
by two factors: (1) the majority of urinary and plasma NE 
is secreted from peripheral sources rather than the brain, 
and (2) an accurate method of measuring brain NE is yet to 
be confirmed (Bunney & Davis, 1965; Schildraut & Kety, 1967). 
One of the most important contributions in 
support of this hypothesis of affective disorders is 
studies in the urinary excretion of 3-methoxy-4-
hydroxyphenolglycol (MHPG). Research has found that 
MHPG is the major metabolite of brain NE. Mannarino, 
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Kirshner, and Nashold {1963) recovered NE, normetanephrine 
(NM), and MHPG in the cerebrum, cerebellum and urine of 
cats following intraventricular injections of NE. The 
principle metabolite in the urine was a conjugate of 
MHPG formed in the liver. Schanberg, Schildkraut, Breese, 
and Kopin (1968) found that after injection of NM in the 
cisterna magna of rats a sulfur conjugate of MHPG was the 
major metabolite found in the brain over time. Also after 
intracisternal injection of NE, the sulfur conjugate of 
MHPG was also found to be the metabolite present in the 
brain, accounting for 30% of the radioactive injection of 
NE. In the dog, a significant fraction of NE, about 25% 
was excreted as MHPG (Maas & Landis, 1968). 
In reviewing the literature, Maas, Fawcett, and 
Dekirmenjian {1972) conclude that the majority of urinary 
NE, NM, and 3-methoxy-4-hydroxymandelic acid (VMA) have 
had their origins in the body pools of NE rather than 
the brain pools. However, MHPG seems to originate pri-
marily in the brain. This theory is substantiated by 
Maas, Hattox, Greene and Landis (1979) who compared 
plasma MHPG taken from the internal jugular vein with the 
plasma MHPG taken from the radial artery. The venous-
arterial difference was significant, implying that MHPG 
comes from the brain. By measuring the arterial-venous 
difference and total blood flow, they were able to esti-
mate that 63% of MHPG excreted in the urine is derived 
from the brain. 
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Because of these findings, measurement of MHPG 
in urines of depressed patients has been employed to 
investigate the catecholamine hypothesis of affective 
disorder. Maas, Fawcett, and Dekirmenjian (1968) com-
pared a group of severely depressed patients with normal 
controls. Urinary levels of MHPG were significantly 
lower for the patient group than the controls. Levels of 
metanephrine (M) and NM which are thought to originate 
from peripheral sources did not differ between groups. 
Maas, Dekirmenjian, and Fawcett (1971) replicated these 
findings. Also Deleon-Janes, Maas, Dekirmenjian, and 
Sanchez (1975) reported that patients diagnosed as having 
primary affective disorder whether bipolar, single 
episode unipolar or recurrent unipolar have significantly 
lower MHPG levels than normal controls. Another classifi-
cation of depression, the psychotically depressed, were 
significantly lower than normals whereas nonpsychotic and 
undiagnosed were not different. Agitated in comparison 
to retarded depressions showed no difference in MHPG. 
There is apparent agreement among researchers that some 
depressed patients excrete less than normal levels of 
MHPG. 
Shifts in MHPG levels are also seen in manic-
depressive patients. Deleon-Janes, Dekirmenjian, and 
Fawcett (1973) studied a manic-depressive patient over a 
cycle of two depressive phases alternating with two manic 
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phases. They reported that mean MHPG level for depressive 
period was 805, standard deviation (SD)=45 ~g per 24 hours; 
the mean for the manic phases was 1182, SD=49 ~g per 24 
hours. Urinary MHPG increased prior to the switch to 
mania. Similarly, Post, Stoddard, Gillin, Buchsbaum, 
Runkle, Black, and Bunney (1977) found lower MHPG levels 
during depressive episodes than during manic episodes in 
a single manic-depressive patient. The MHPG levels did 
not change prior to the switch, however, as in Deleon-
Janes et al. (1973). 
The MHPG levels in depressed patients have also 
been found to fluctuate with drug therapy. Greenspan, 
Schildkraut, Gordon, Baer, Aronoff, and Durell (1970) 
studied MHPG in manic-depressive patients treated with 
lithium. Pretreatment, agitated depressed patients had 
significantly lower MHPG levels than either hypomanic 
or normothymic patients; also VMA levels were lower in 
the agitated depression group. During treatment, the 
hypomanic group showed decreases in MHPG whereas the 
agitated depression group showed a significant increase 
in MHPG. Both hypomanic and depressed patients had 
significantly decreased NE, NM, E, M, and VMA levels. 
The authors suggest that MHPG is associated with brain 
NE and depression whereas the heightened agitation, 
anxiety, motor activity found in this type of patient 
would be associated with the increase in NE, NM, E, and 
M arising from an increase in peripheral activity. 
Also Fawcett, Maas and Dekirmenjian (1972) found 
a significant negative correlation between behavioral 
improvement after administration of dextroamphetamine 
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and tricyclic antidepressant drug treatment and low pre-
treatment MHPG excretion. Five of six patients who were 
rated as improved by physicians and staff showed a slight 
increase in MHPG after dextroamphetamine treatment while 
five of six nonresponders showed a decrease in MHPG. Low 
pretreatment MHPG excretion and improvement in depression 
ratings were correlated significantly, reaching .58 after 
three weeks and .84 after four weeks of tricyclic drug 
therapy. Maas, et al. (1972) reported that depressed 
patients who responded to imipramine with improved 
depression ratings had lower pretreatment MHPG excretion 
than nonresponders who were in the normal range. 
Furthermore, Beckmann and Goodman (1975) measured 
MHPG in 24 unipolar depressed patients, 16 of whom were 
treated with imipramine and eight of whom were treated 
with amitriptyline. The nine imipramine responders were 
significantly lower in MHPG than the seven nonresponders. 
For the amitryptyline patients, responders had signifi-
cantly higher predrug MHPG levels. The group as a whole 
showed a significant decrease in MHPG after treatment 
which contradicts the findings of the Maas group. 
These studies suggest that depression is a 
heterogenous disease since some but not all depressives 
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differ from normals and since there are various responses 
to drug therapy among depressed patients. Maas (1975) 
concludes that there might be two types of depressed 
individuals: a type A patient who has (a) lower pre-
treatment MHPG levels, (b) a positive response to 
imipramine, (c) an elevation of mood from dextro-
amphetamine, and (d) little or no increment in MHPG after 
treatment; and a type B patient who has (a) normal or 
high MHPG, (b) favorable response to amitriptyline, 
(c) a lack of mood change from dextroamphetamine, and 
(d) decrements in urinary MHPG following treatment with 
imipramine or dextroamphetamine. 
A number of studies of MHPG in cerebrolspinal 
fluid (CSF) do not support the catecholamine hypothesis 
of affective disorder. They report that depressed 
subjects had CSF MHPG levels within the normal range 
(Shopsin, Wilk, Sathananthan, Gershon, & Davis, 1974; 
Wilk, Shopsin, Gershon, & Shul, 1972). Wilk et al. (1972) 
found that manic-depressives (N=6) had significantly 
higher MHPG levels; three subjects, however, were in the 
normal range. These studies added to those reporting 
various responses of depressive to drug treatment suggest 
that the relationship between MHPG levels and affect is 
not a straight line relationship. 
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There are three recent studies of MHPG which are 
directly relevant to this present study of normal women 
during the menstrual cycle. Since the present study will 
be concerned with normal subjects rather than depressed, 
data collected by Hollister, Davis, Overall, and Ander-
son {1978) on MHPG excretion in normal subjects are most 
relevant. The range of mean values for 17 subjects was 
l ,316 to 4,252 ~g per 24 hours. Coefficients of variation 
calculated from each subject•s three consecutive 24 hour 
collections ranged from 3.1% to 23%. Less than five 
percent of the time was an individual•s second value 
ta~en after a lapse of several weeks different_from the 
first by more than+ 1,760 ~g. It was estimated that 
approximately 95% of all 24 hour collections for the 
normal population would fall between 900 and 3,525 ~g. 
No statistically significant effects were found for sex 
of subject. Earlier, DeLeon-Janes et al. (1975) reported 
approximately 1,300 ~g normal for women; and Maas et al. 
{1968) reported 1,700 normal for men. 
Another recent publication (Sweeney, Maas, & 
Heninger, 1978) which is highly relevant to this present 
study measured urinary MHPG and state-anxiety in 24 
depressed patients. The measure for state-anxiety was 
the STAI (Spielberger et al., 1970) which was also used 
in this present study. Patients were placed in an 
increased activity or a restricted activity group. There 
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were no differences in MHPG or in state-anxiety on account 
of activity group across the control, experimental, and 
post experimental periods. Change scores from the con-
trol to experimental periods were computed for urinary 
MHPG and for state-anxiety and yielded a correlation of 
.85 for the active group and .68 for the restricted group. 
Increases in state-anxiety were associated with increases 
in MHPG. Those who showed increases in anxiety and in 
MHPG had a lower baseline MHPG than those with higher 
levels who showed decreases in anxiety and MHPG. The 
authors point out that it cannot be predicted that those 
with low baseline MHPG will have low state-anxiety. They 
also point out the anxiety-MHPG levels relationship 
emerged when there was a treatment intervention rather 
than within the natural course of events. 
When studying MHPG in normal women during the· 
menstrual cycle, DeLeon-Janes, Steinberg, Dekirmenjian, 
and Garver (1978) found a significant increase in MHPG 
at days -5,-4,-3 prior to menses and a decline in MHPG at 
days -2 and -1 prior to menses. This work was viewed as 
preliminary to this present study since there were only 
four subjects and no attempt was made to determine 
ovulation. 
In review, five issues can be emphasized which 
led to the hypotheses of this study: (1) MHPG is a likely 
36 
measure of CNS NE since 63% of MHPG comes from the brain, 
(2) an increase in NE is associated with the LH surge 
requisite for ovulation, (3) an increase in MHPG has 
been noted on days -5,-4,-3 prior to menses, {4) psycho-
logical studies suggest that there is an increase in 
positive affect at ovulation and an increase in anxiety 
and depression at the premenstruum; and (5) lower levels 
of NE as measured by MHPG are associated with depression 
while increases in MHPG are associated with elation and 
anxiety. 
Hypotheses 
1. Urinary MHPG peaks during the ovulatory phase. 
2. The MHPG level peaks during days -5,-4, and -3 
prior to menses. 
3. State-anxiety peaks at ovulation in relation to a 
peak in MHPG. 
4. State-Anxiety peaks at days -5,-4, and -3 prior to 
menses in relation to a peak in MHPG. 
5. Menstrual Distress (MDQ Total Score) peaks at the 
premenstruum as suggested by psychological research 
on the menstrual cycle. 
6. Depression (MDQ Negative Affect) increases at the 
premenstruum in relation to a low point in MHPG levels. 
7. Pleasant Affect (MDQ Arousal) peaks at ovulation in 
relation to a peak in MHPG. 
8. The MHPG level correlates positively with state-
anxiety as suggested by previous research with 
MHPG and state anxiety. 
9. The MHPG level correlates negatively with MDQ 
Negative Affect as suggested by previous research 
with MHPG and depression. 
10. MHPG correlates positively with positive affect as 
suggested by the expectation that MHPG elevations 





The 11 women who served as subjects in this study 
were selected from volunteers from the student body and 
staff of the University of Illinois Medical Center. 
Advertisements were posted throughout the Medical Center. 
They were paid $30 for one month's participation, $60 for 
two months, and $100 for three months. The prerequisites 
for inclusion in the study were that the women were free-
cycling, that they had not been taking any form of oral 
contraceptives within the last six months nor were they 
less than 12 months post-lactation. By questionnaire of 
medical history, the women were screened to exclude any 
known endocrine, renal, cardiovascular, gasteroentric 
dysfunction or urogenital infections. Also women with 
any gynecological disturbances such as amenorrhea, 
hypomenorrhea, or hypermenorrhea were excluded. Women 
on any form of continuing medication were excluded. Each 
volunteer had a brief psychiatric interview to determine 
whether she had a prior or current psychiatric disturbance. 
Women with a current or previous diagnosis of depression, 
schizophrenia, or severe anxiety disturbance were 
excluded since the purpose of the study was to investigate 
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the menstrual cycles of normal women. Three women were 
originally excluded because of this criterion. 
Of the 15 women who participated in the study, 
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four were eliminated from the statistical analysis. Two 
women were considered anovulatory because their tempera-
ture charts were uninterpretable. One woman had incomplete 
urine collections. Another woman was excluded because in 
a post experimental interview, she revealed that she had 
a history of manic-depressive illness. 
The following demographic information was obtained 
for the remaining subjects. The mean age was 25, 
SO = 4.09; the age range was 19 to 35. Seven women were 
single; four were married. Ten women were nulliparous and 
one woman multiparous. All women reported regular cycles 
with nine having 27-29 day cycles, one with 30-32 day 
cycles and one with 33+ day cycles. 
Measures 
State-Trait Anxiety Inventory {Spielberger, Gor-
such, & Lushene, 1970). The Anxiety-State (x-1) scale 
consists of 20 statements about emotional states with 
instructions to subjects to describe how they feel at that 
particular moment. They are to evaluate their feelings 
from one to four, from 11 Not at All 11 to "Very Much So. 11 
The concept of anxiety measured is 11 the transitory 
emotional condition ... of consciously perceived 
feelings of tension and apprehension and heightened 
autonomic nervous system activity 11 (Spielberger, et al., 
1970, p. 3). The Anxiety-Trait (x-2) scale consists of 
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20 items by which people report how they generally feel. 
Trait-anxiety refers to individual differences in dispo-
sition to respond to stressful events with varying amounts 
of state-anxiety. For state-anxiety, test-retest corre-
lations range from .16 to .54, reflecting the sensitivity 
of the test to the situational factors at the time of the 
testing. For trait-anxiety, test-retest correlations are 
.73 to .86. Using the alpha coefficient as a measure of 
internal consistency, results for state-anxiety range 
from .83 to .92 and for trait-anxiety from .36 to .96. 
Menstrual Distress Questionnaire (Moos, 1968) 
Form T. This is a list of 47 symptoms related to the 
menstrual cycle. Women are asked to rate the symptoms 
as they are experiencing them that day. Subjects rank 
each symptom from one to six from 11 no experience of the 
symptom 11 to 11 acute or partially disabling. 11 The 47 items 
were factor analyzed and intercorrelated with a sample of 
839 women who were asked to describe their menstrual 
cycle at three phases and their worst menstrual cycle. 
Eight factors were differentiated: pain, concentration, 
behavior change, autonomic reactions, water retention, 
negative affect, arousal, and control. Intercorrelations 
between the eight scales are all positive ranging from 
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.59 between pain and negative affect to . 18 between 
arousal and autonomic reactions. Split-half reliabilities, 
which varied from .74 to .98 were all statistically signi-
ficant (Markum, 1976). The manual gives normative data 
for Form A which is based on a report of how a woman feels 
in retrospect about three different phases of her cycle. 
The manual then states that the means and standard devia-
tions for Form T, which has instructions to report 
symptoms for that day, are similar to Form A. 
Procedure 
When each woman volunteered, an interview appoint-
ment was arranged for her. During this interview, it was 
determined whether or not she would participate on the 
basis of her medical and psychological history. The few 
necessary questions about contraceptives and the length 
and regularity of the menstrual cycle were also inter-
woven- into this interview. At this time the subjects 
were notified that they would collect 24-hour urines 
and record their feelings daily. They were asked not to 
take any medication unless directed by a physician and 
then to notify the experimenters so that they could be 
dropped from the experiment. To agree to this, all 
subjects signed a consent form to participate for approxi-
mately 35 days in the study. 
If accepted according to the criteria mentioned 
above, the subject began the procedures the following 
day. By starting at a random point in each woman's 
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cycle, there was some attempt to control for stereotypic 
responses on the daily self-reports. Each woman collected 
urines for a 24-hour period for each day of her cycle. 
The first specimen of the day was taken upon rising and 
added to the previous days collection. Completeness of 
collections were checked through volume measurement and 
creatinine determinations. Urines were assayed for MHPG 
by the method of Dekirmenjian and Maas (1970) and 
creatinine by the method of Bonsnes and Taussky (1945). 
Also each subject was instructed to take her 
basal body temperature before rising from bed each 
morning. She was instructed to fill out a state-anxiety 
form and an MDQ form each evening before retiring. These 
were labelled x-1 and Form T respectively. She also 
recorded the most significant event of each day and noted 
the days on which she menstruated. This notation about 
menstruation, she was told, was to assist the laboratory 
in analyzing the urine. Since she had to bring in her 
urines every other day, she also brought in her daily 
self-reports at this time. Each week the experimenter 
called each subject to discuss and work out any diffi-
culties. One subject had a broken thermometer at one time. 
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At the end of a period the approximate length 
of her cycle, each subject came in for another interview. 
At this time she was told she could continue in the study 
if she wished. If she did continue, she followed the 
same instructions. If she did not, she filled out a 
detailed questionnaire on her menstrual history and 
attitudes and on her family medical and psychiatric 
history. Then the subject was paid. Three subjects par-
ticipated for three cycles. 
Subjects were also asked what they thought the 
study was about and what their reactions were to the 
procedures. Of the 11 subjects, five said that the study 
had something to do with moods during the menstrual cycle. 
No major life events occurred for any of the subjects 
during the course of the study. 
Partitioning of the Cycle. For statistical 
analysis the cycle was divided into six phases. To make 
the cycles uniform for each subject, the days of the cycle 
were used in the following order: (1) the first five 
follicular days; (2) three ovulatory days with the middle 
day viewed as ovulation; (3) the first five luteal days; 
(4) days -5,-4, and -3 prior to menses as late luteal 
days; (5) days -2 and -1 prior to menses as premenstrual 
days; and (6) the first five menstrual days. Ovulation 
was determined by basal body temperature. Urinary preg-




Variations in MHPG 
The mean urinary MHPG level for the ll subjects 
was 1486.35, SO = 297.87, ~g per 24 hours. The range of 
subjects' means was 876.11, SO= 240.90 vg per 24 hours 
for the lowest individual level to 1925.73~ SD = 370.90 
for the highest individual level. Only one subject fell 
slightly below the estimated normal range of 900 to 3,525 
~g per 24 hours (Hollister et al., 1978). It compares 
with the 1300 ~g per 24 hours for women reported by 
Deleon-Janes et al. {1975). Table 1 gives mean MHPG 
levels for all subjects. 
Hypothesis 1, that urinary MHPG peaks during the 
ovulatory phase, was supported at the .0002 level of 
significance. Hypothesis 2, that urinary MHPG peaks 
during days -5,-4,-3 prior to menses was also supported 
at the .0002 level of significance. Means are found in 
Figure 3a. 
An analysis of variance for repeated measures 
indicated a significant phase effect, F (5, 48) = 6. 12, 
Q<.0002. Trend analysis indicated a significant quartic 




Mean Excretion of MHPG in ~g per 24 Hours 
Subject Mean MHPG SD 
1 1792.50 325.40 
2 1925.73 379.90 
3 1304.48 284.50 
4 1108.20 209.83 
5 1834.82 408.70 
6 1865.27 295.64 
7 1039.71 279.73 
8 876.11 240.82 
9 1544.19 428.78 
1 0 1375.81 365.47 
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Figure 3. Mean scores of MHPG, state-anxiety, MDQ total, and 
MDQ water retention for six phases: follicular, F; ovulatory, 0; 
luteal, L; late luteal,LL; premenstrual, P; menstrual, M. 
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TABLE 2 
Trend Analysis for MHPG, State-Anxiety, 
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TABLE 2 (continued) 
Source df HS F p 
MDQ Total 
Phase 5 261.75 1.83 NS 
Quartic Trend 1 939.64 6.55 .05 
Dev from Quartic l 4.84 .03 NS 
Phase x Subject 47 143.36 
MDQ Water Retention 
Phase 5 41.91 10.58 .0001 
Linear Trend 1 113.51 28.66 .05 
Dev from Linear 4 24.02 6.06 .05 
Quadratic Trend 1 31.99 8.08 .05 
Dev from Quad 3 21.35 5.39 .05 
Cubic Trend 1 54.79 13.83 .05 
Dev from Cubic 2 4.64 1.17 NS 
Phase x Subject 48 3.96 
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quartic was also significant, F (1, 48) = 19.79, p<.05. 
Newman-Keuls test for ordered differences (Table 3) 
indicated that the late luteal phase was significantly 
higher (£<.05) than the luteal, follicular, and menstrual 
phases. Also the ovulatory phase was significantly 
higher (£<.05) than the follicular and the luteal phases. 
Of the 11 subjects, 91% showed peaks at the ovula-
tory phase, 55% at the late luteal phase. Fifty-five per-
cent of the women showed both peaks that had been hypothe-
sized. Figure 4 shows the variation in patterns for the 11 
subjects for MHPG and the psychological measures. 
Variations in the Psychological 
Variables 
State-Anxiety 
For state-anxiety, the grand mean was 35.50, 
SD = 7.21. This is comparable (!(450) = .48, £>.05) to 
the mean of unstressed female college students, 35. 12, as 
reported by Spielberger et al. (1972). The premenstrual 
mean was 40.41, SD = 9.90. Premenstrual state-anxiety 
was equivalent (!(668)= 1 .36, £>.05) to the anxiety of 
female freshmen (M = 39.39) during an orientation week, as 
presented in the normative data (Spielberger et al., 1972). 
Hypothesis 3 that state-anxiety peaks at ovulation 
in relation to a peak in MHPG was supported at the .05 
level of significance. Hypothesis 4 that state-anxiety 
TABLE 3 
Tests on MHPG Means Using the Newman-Keuls Procedure 
L F M p 0 LL r 
L 36.42 139.98 169.21 333.03 347.09 6 
F 103.57 132.78 296.61 310.67 5 
M 29.23 193.04 207.10 4 
p 163.81 177.87 3 
0 14.06 2 
s = 60.77 
-p 
r = 2 3 4 5 6 
S_q (r,48) 
p 












Note: - Abbreviated F=follicular; O=ovulatory; l=luteal; 
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Figure 4. Subject means for MHPG, state-anxiety, and MDQ total 
during the six phases: follicular, F; ovulatory, 0; luteal, L; 
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peaks at days -5,-4,-3 prior to menses in relation to a 
peak in MHPG was not supported. Another peak in state-
anxiety was found at premenses (Figure 3b). A quartic 
trend was significantly predictive of these two peaks at 
ovulation and premenses, f(l, 48) = 5.04, ~<.05. Analysis 
of variance for repeated measures across the six phases 
was computed; the phase effect was not significant. 
Fifty-five percent of the women peaked at ovula-
tion. Sixty-four percent peaked at the premenses. Only 
18% peaked at both. Only one person showed the identical 
peaks in MHPG and state-anxiety. (Figure 4) 
Menstrual Distress Questionnaire 
Hypothesis 5 that MDQ total peaks of the premen-
struum was supported at the .05 level of significance. 
MDQ total also peaked during the ovulatory phase (Figure 
3c). Trend Analysis indicated a significant quartic 
trend, f (1, 47) = 6.55, £<.05 (Table 2). Analysis of 
variance for repeated measures across the six phases did 
not show a significant phase difference. The premenstrual 
mean, 76.41, was equivalent to the premenstrual mean, 
73.80, presented in the MDQ manual (Moos, 1977), 
t (21) = .24, £>.05. 
Of the 11 subjects, 45% peaked at ovulation. At 
premenses, 65% showed elevated MDQ scores (Figure 2). 
The same 45% had an elevation in MHPG at ovulation. At 
premenses, only 27% had an elevation in MHPG and MDQ total. 
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Hypothesis 6, that depression increases at the 
premenses was not supported. Also, Hypothesis 7 that 
pleasant affect increases at ovulation was not supported. 
Of the other MDQ factors--pain, concentration, 
behavior change, autonomic response, and water retention--
only water retention showed significant phase changes. 
Analysis of variance for repeated measures yielded a 
significant phase effect, F (5, 48) = 10.58, £<.0001. 
Tests for trend indicated a significant linear trend, 
F ( 1 ' 48) = 28.66, £<.05; a significant quadratic trend, 
F ( 1 ' 48) = 8.08, £<.05; and a significant cubic trend, 
F ( 1 ' 48) = 13.83, £.<.05. Deviation from cubic was not 
significant. As can be seen in Figure 3d, water reten-
tion shows a continuous rise from the follicular phase to 
premenses. 
Correlations: of MHPG with the 
Psychological Variables 
Pearson product-moment correlations between MHPG 
and the psychological variables--state-anxiety, MDQ total, 
MDQ negative affect, and MDQ arousal--were computed for 
each subject. The average ~was then obtained by means of 
Fischer's r to z conversion. The following hypotheses 
were not supported: (1) hypothesis 8 that MHPG correlates 
positively with state-anxiety (~ = .03 £>.05); 
(2) hypothesis 9 that MHPG correlates negatively with 
MDQ negative affect (~ = .07, £.>.05); and (3) hypothesis 10 
that MHPG correlates positively with MDQ arousal, a 
measure of pleasant affect(!= .04 p>.05). 
Another correlation computed between MDQ total 
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and MHPG was not significant either. The three corre-
lations between state-anxiety and the MDQ variables showed 
significant intercorrelations: (1) state-anxiety with 
MDQ total, ! = .41, £<.001; (2) state-anxiety with nega-
tive affect, r = .81, .e_<.OOl; state-anxiety with arousal, 
r = 0.31, £<.001. 
Since it was not expected at this point that the 
relationship between urinary MHPG and the psychological 
variables would be a simple linear relationship within 
individuals, various ways of correlating the biochemical 
variables with psychological variables were undertaken 
as preliminary investigation for future research. By 
inspection of Figure 1 it was noted that the relation-
ships at the first half of the cycle between MHPG and the 
psychological variables looked positive. At the second 
half, they appeared to be negative relationships. Hence 
it was suspected that any significant linear correlations 
within an individual would be cancelled out across the 
cycle. 
Daily group means from days 6-11 and days 14-21 
were correlated between MHPG and the four psychological 
variables. (Table 4) These days were chosen because 
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They were also sequential whereas other days had been 
dropped out of the follicular and luteal phases to 
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create uniformity of cycle. Three sets of correlations 
were done: (1) same-day, (2) MHPG time-lagged one day 
behind each psychological variable, (3) each psychological 
variable time-lagged one day behind MHPG. 
Only one of the eight same day correlations was 
significant. For days 6-11, MHPG correlated with negative 
affect, .!:.. = .93, E_<.05. These correlations did not· 
indicate a trend. 
With MHPG time-lagged behind each pshcyological 
variable, correlations were positive days 6-11 and negative 
days 14-21. For MHPG/MDQ Total, .!:.. = .87, E_<.05 at days 
6-11. For MHPG/MDQ negative affect at days 14-21, 
r = -.84, E_<.05. 
For the psychological variables time-lagged 
behind MHPG, the correlation coefficients are predomi-
nantly positive. At days 14-21, for MHPG/HOQ negative affect, 
.!:.. = .81, E_<.05. Also, for MHPG/MDQ Total,.!:..= .75, 
E_<.05. Since so many correlations were done, these results 
were interpreted with caution. 
In order to decrease individual variability and to 
investigate the phase effect on the relationship between 
MHPG and the psychological variables, Pearson product-
moment correlations were computed with the phase means 
from each subject at each phase. No significant 
correlations were found. When these means were plotted 
for state-anxiety and MHPG, it was noticed that those 
subject who had a mean MHPG excretion of less than 
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1700 ~g per 24 hours during a given phase, exhibited a 
different relationship between the psychological and the 
biochemical variables than those who had a mean excretion 
level above 1700. (Table 5) Correlation coefficients 
increased for high and low excreters when the two groups 
were analyzed separately. At ovulation for low excreters, 
a significant negative correlation, r = -.96, (N=5) p<.05. 
was found. For high excreters,~= .66, Q>.05 {N=6). 
At premenses, a significant positive correlation was found 
for low excreters,~= .66, Q<.05 (N=8). At premenses 
there were only three high excreters; therefore the 
correlation coefficient was not computed. The cycle means 
for low excreters (N=7) were correlated for state-anxiety 
and MHPG resulting in~= .70 Q<.05. For high excreters 
(N=4), ~ = -.07, Q>.05. For the group as a whole, 
~ = .024, £>.05. Differences between high and low 
excreters were not as apparent when the MDQ variables 
were correlated with high or low MHPG excretion level. 
TABLE 5 
Phase Correlations for High and Low Excreters 
Phase High Low All 
State-Anxiety/MHPG 
Follicular -. 21 ( 4) .57 (7) -.11 
Ovulatory .66 ( 6 ) -.96*(5) -. 1 3 
Luteal .59 ( 7 ) .06 
Late Luteal . 71 ( 6 ) -. 14 ( 5 ) -.01 
Premenstrual .66*{8) . 01 
Menstrual -.20 ( 9) .51 
MDQ Total/MHPG 
Follicular .80 ( 4) .39 ( 7 ) .05 
Ovulatory -.04 ( 6) -.86 ( 5 ) .38 
Luteal -. 1 4 (7) -.03 
Late Luteal -.42 ( 6) .75 ( 5 ) . 15 
Premenstrual -.47 (8) -.09 
Menstrual -. 18 (9) -.04 
MDQ Negative Affect/MHPG 
Follicular -.69 ( 4) -.28 ( 7 ) -. 21 
Ovulatory .35 ( 6 ) -.58 ( 5 ) -.39 
Luteal -.32 ( 7 ) -.33 
Late Luteal -.73 ( 6 ) -.32 ( 5) -.05 
Premenstrual -.28 ( 8) . 1 7 
Menstrual .01 ( 9 ) -.11 
MDQ Arousal/MHPG 
Follicular .31 ( 4 ) -.27 (7) -. 21 
Ovulatory -.07 ( 6) .73 ( 5) . 16 
Luteal -.28 ( 7 ) -.26 
Late Luteal .56 ( 6) .43 ( 5 ) -.04 
Premenstrual .26 (8) -.03 
Menstrual -. 11 ( 9) -.06 





In summary of the major findings, urinary M~PG 
peaked at ovulation and the late luteal phase of the 
menstrual cycle. The psychological measures, state-
anxiety and MDQ Total peaked at ovulation and premenses. 
The MDQ Negative Affect and Arousal (pleasant affect) 
did not show phase related changes during the menstrual 
cycle. Correlations between urinary MHPG and the psycho-
logical variables suggest a complex relationship between 
urinary MHPG and the psychological variables. 
Variations in MHPG 
The e 1 eva t i on of uri nary M H P G d uri n g the o v u 1 a t_o r y 
phase supported the theory that the neurotransmitters of 
the CNS play a significant role in stimulating ovulation 
in the human female. Since 63% of urinary MHPG has its 
source in the brain (Maas, 1979), measurement of MHPG is 
a particularly direct measure of CNS activity during the 
menstrual cycle. Earlier studies of plasma and urinary 
NE during the menstrual cycle reflected the peripheral 
pools of NE. 
Animal research has dealt directly with brain 
monoamines including NE and their effects on ovulation. 
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Rubinstein and Sawyer (1970) blocked ovulation by 
depleting hypothalamic catecholamines in proestrus rats. 
Sawyer et al. (1974) induced ovulation with an intra-
ventricular dose of NE. Kalra et al. (1972) blocked 
ovulation in estrogen-primed rats with injections of 
drugs known to block brain catecholamines. 
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Measurement of plasma NE in humans, also indicated 
increases at ovulation (Rosner et al., 1976; Zacur et al., 
1978; Zuspan and Zuspan, 1972). Badano et al. {1978), 
taking blood samples every eight hours for the three days 
before ovulation, found an estrogen peak, followed by a 
peak in NE, followed by an LH surge. In this same study, 
two anovulatory women had higher and more variable NE 
levels during the follicular phase than ovulatory women. 
Apparently, an increase in estrogen followed by an 
elevation in NE induces an LH surge. The increase in 
MHPG levels at the ovulatory phase in this study is added 
evidence for the involvement of brain NE in ovulation. 
In this study, urinary MHPG also peaked signi-
ficantly at days -5,-4, and -3 before menses which had 
previously been reported by Deleon-Jones et al. (1978). 
Progesterone is known to increase during the luteal 
phase. Estrogen also shows a secondary rise at this time. 
A preliminary investigation of the relationship 
between MHPG and progesterone, as estimated by pregnanediol 
measurement, was undertaken. Since this study did not 
take all pregnanediol levels from ovulation to menses, 
the composite is only suggestive of the relationship 
between increased progesterone and MHPG (Figure 5). 
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It can be seen by inspection that progesterone peaked 
during the luteal phase sometime after the sixth day post 
ovulation. Progesterone began its descent during the late 
luteal phase. All women maintained relatively high levels 
until premenses. Two women maintained high levels until 
menstruation. 
The MHPG levels peaked after the progesterone 
levels began to decline. Other studies have also found a 
postovulatory elevation in NE (Zuspan & Zuspan, 1973; 
Zuspan & Rao, 1974). Also increased MAO activity has 
been related to increased progesterone levels during the 
late luteal phase (Southgate et al., 1968). Progesterone 
therapy increased MAO activity in amenorrheic and post-
menopausal women (Klaiber et al ., 1971). Oral contra-
ceptives with progesterone compounds produced high MAO 
activity in endometrial tissue (Grant & Pryse-Davis, 
1968). Furthermore, MHPG results from the deamination 
of NE by MAO enzymes. Therefore increases in MHPG during 
the late luteal phase may reflect the same interaction 
between NE and progesterone as the increases in MAO 
activity during the luteal phase. 
In conclusion, MHPG levels peaked at ovulation 
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Figure 5. A composite of daily urinary excretion of MHPG and 
pregnanediol excretion during the menstrual cycle. Each value 
is the mean for 11 subjects. 
Note: Abbreviated M=menstrual; F=follicular; O=ovulatory; 
L=luteal; LL=late luteal; P=premenstrual. 
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and when progesterone is known to increase. This is 
followed by a secondary rise in estrogen and a rise in 
progesterone during the luteal phase. MHPG levels 
appeared to peak after the ovarian hormones began to 
decline in the late luteal phase. Explanation for this 
apparent relationship must be found in future research 




The psychological variables of state-anxiety and 
MDQ total showed significant peaks at ovulation and pre-
menses. State-anxiety is a measure of awareness of 
tension and heightened autonomic nervous system activity. 
The MDQ total score is a measure of symptoms popularly 
associated with menstruation. 
The premenstrual peak in state-anxiety and MDQ 
total substantiated most of the literature of the varia-
tions in mood during the menstrual cycle. Correlational 
studies have repeatedly shown exacerbation of symptoms 
at premenses (Dalton, 1960; Dalton, 1961; Dalton, 1964; 
Glass et al., 1971; Mandell & Mandell, 1967; Ribeiro, 
1960; and Tonks et al., 1967). Many studies have 
contrasted midcycle to premenses or menses. They have 
frequently found a U-shaped curve of increased symptoms 
at menses, low at midcycle and high at premenses. For 
anxiety, Ivey and Bardwick (1968), Moos et al. (1969}, 
and Silbergeld et al. (1971) found increases at the 
premenses. Using the STAI, Golub (1976) found signi-
ficantly higher premenstrual state-anxiety scores than 
intermenstrual score. For MDQ total, Moos (1977) showed 
higher premenstrual scores than intermenstrual scores. 
The MDQ negative affect, however, did not signi-
ficantly peak at premenses as was hypothesized. Paige 
(1971) found a premenstrual increase in negative affect 
with another measure. Golub (1976) found an increase in 
depression at premenses on the DACL (Lubin, 1967) when 
comparing premenses with intermenses. Moos (1977) 
reported elevated negative affect at the premenses from 
retrospective questionnaries. On the other hand~ 
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Moos et al. (1969) reported no cyclic changes in 
depression as did Silbergeld et al. (1972) using the MDQ. 
In this present study, subjects did not have any history 
of depressive symptoms. They also scored highest on 
MDQ arousal, a measure of pleasant affect, throughout 
the cycle. Perhaps since the scale contains only eight 
items, it would be relatively insensitive to daily 
changes. Golub (1976) reported changes in depression 
levels using the DACL (Lubin, 1967) which has been shown 
to be sensitive to daily changes in depression. Among 
other differences from the MDQ negative affect scale, 
the DACL has 18 items. 
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On the other hand, evidence for increase in 
depression at premenses is insubstantial. Golub (1976) 
compared single measures from the premenses and inter-
menses. A valid comparison cannot be made to intermenses, 
since the term intermenses could refer to follicular, 
ovulatory or luteal activity, all of which have different 
hormonal balances. In addition, Moos {1977) who reported 
changes in negative affect was reporting data collected 
from retrospective questionnaires which were strongly 
subject to cultural stereotypy about the menstrual cycle. 
Contrary to earlier findings in the psychological 
studies mentioned above, the present study found a peak 
in state-anxiety and MDQ total at ovulation. Altman 
et al. (1939) had found that 67.5% of their subjects 
retrospectively reported experiencing ovulation with 
elation, with only 31% reporting some tension at ovulation. 
Also increased sociability and sexual arousal have been 
found during the ovulatory phase {Moos et al., 1969; 
Luschen & Pierce, 1972). However, Benedek and Rubenstein 
(1939) did note increased tension and irritability as 
ovulation approached which would support these present 
findings of increased anxiety and menstrual distress. 
In the past, many studies of psychological changes 
during the menstrual cycle have compared menses and pre-
menses to intermenses. This can obscure difference since 
those measures could have been taken during the follicular, 
ovulatory, or luteal phases. Both the follicular and 
luteal phases appear to have lower levels of symptoms. 
Other studies have used a particular day prior to menses 
such as -14 as ovulation which because of individual 
differences in time of ovulation, would be inaccurate 
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for many subjects. Another method has been to divide the 
cycle into equal segments and compare these segments 
statistically. All these methods could miss an elevation 
in anxiety and menstrual distress symptoms which occurs 
at a very short time at ovulation. In general, documen-
tation of ovulation by means of basal body temperature, 
hormone determinations, or LH levels must be done in 
order to carry out menstrual cycle research. 
The MDQ water. retent1on .was the only factbr on the 
MDQ which changed significantly during the cycle, showing a 
gradual rise from the follicular to the premenstrual phase. 
The women reported an increase in all symptoms within the 
factor-weight gain, skin disorders, painful breasts, and 
swelling. Janowsky et al. (1973) also reported significant 
weight gain at the premenstruum. Furthermore, Wilcoxon 
et al. (1976) found significant increase in the physio-
logical symptoms of pain and water retention at premenses. 
Pearson product-moment correlations between 
state-anxiety and the three MDQ variables--total score, 
negative affect and arousal--were significant. State-
anxiety was positively correlated with MDQ total and 
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and negative affect. State-anxiety was negatively 
correlated with MDQ arousal (pleasant affect). That these 
relationships occurred lends concurrent validity to the 
measures as one would expect them to correlate. 
Correlations were first computed for each individual 
and then averaged by means of a Fischer's r to z con-
version. Hence, the final correlation coefficient 
reflects the inner consistency within each subject as 
well as the relationship between state-anxiety and the 
MDQ variables. 
The results of the statistical analyses of these 
psychological variables indicated that normal women have 
changes in levels of state-anxiety and changes in a 
syndrome called "menstrual distress" at ovulation and 
premenses. Both measures, the STAI and the MDQ, measure 
negative affect, tension, and heightened physiological 
activity. It would appear from this study that the incre-
mental accumulation of symptoms both psychological and 
physiological rather than any particular measure such as 
negative affect accounts for the elevations at ovulation 
and premenses. 
Each variable on the MDQ remained consistent 
from phase to phase. Across the cycle physiological 
measures accounted for from 40 to 45% of the total score; 
42.5% of the items pertained to physiological symptoms. 
Arousal accounted for about 17% of the total score with 
10.6% of the items within the arousal factor. Negative 
affect accounted for 17% of the total score with 17% of 
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t h e i t em s . No o n e o f t h e s e fa c to r s s e e me d t o c h a n g e t he 
proportion alotted to that factor at any given phase. 
Therefore it appeared that psychological and physiological 
measures accounted for a consistent amount of the total 
score throughout the cycle. Hence MDQ total would repre-
sent a syndrome called 11 menstrual distress 11 which shows 
fluctuation during the cycle. 
Although the elevations at ovulation and premenses 
for state-anxiety and MDQ total are statistically signi-
ficant for the group, it must be noted that individuals 
do differ from the group patterns as was seen in Figure 4. 
On the STAI, only 18% peaked at both ovulation and 
premenses. On the MDQ, 45% showed these peaks. Only one 
subject has these elevations on both measures. As a 
result, these findings of a significant quartic trend 
for both measures must be interpreted with caution. 
Correlations Between MHPG and 
the Psychological Variables 
Correlations between MHPG and the four psycho-
logical variables were computed for each subject. The 
group correlations, averages of subjects• correlation 
coefficients computed by means of Fischer's r to z 
conversion, were not significant. These findings 
suggest that the relationship between MHPG and each 
psychological variable is not a simple linear relation-
ship within an individual. No other studies to date 
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with either depressed or normal subjects have tested 
whether repeated measures of MHPG without a treatment 
intervention correlate with simultaneous repeated measures 
of a psychological variable. Hollister et al. (1978) 
reported a range of urinary MHPG between 1 ,003 to 
6,276 ~g per 24 hours when taking repeated measures of 
normal subjects. They were asked about their mood at each 
time of MHPG measurement. Their mood tended toward a 
middle range despite MHPG level. 
Studies with depressed patients have shown that 
they have lower MHPG levels than controls (Maas et al., 
1968; Deleon-Janes et al., 1975). Also manic-depressives 
showed lower MHPG levels during the depressive phase of 
the illness than during the manic phase (Deleon-Janes 
et al., 1973; Greenspan et al ., 1970; Post et al., 1977). 
These studies suggest that when MHPG levels go down, 
depression increases. 
Other studies, however, have found that depres-
sives of various categories do not differ from normals 
when taking CSF MHPG measures (Shopsin et al., 1974; 
Wilk et al., 1972). In Fawcett et al. (1972) only three 
depressives were below the range in urinary MHPG found 
in this present study of normal women. In Sweeney 
et al. (1978) no depressed subjects had lower means than 
the normal women in this study who had no depressive 
symptoms. These contradictory results indicate that low 
levels of MHPG are not necessarily related to increases 
in depression. The present study also found no direct 
linear relationship between urinary MHPG and negative 
mood. 
One previous study (Sweeney et al., 1978) found 
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a significant positive correlation between MHPG and state-
anxiety (STAI). These correlations were based on change 
scores from a pre-experimental to an experimental condi-
tion. This present study, however, did not find correla-
tions between MHPG and state-anxiety when taking repeated 
measures over a long period of time without treatment 
intervention. Nor did subjects• phase means of MHPG 
and state-anxiety correlated at each phase result in 
significant relationships. This additional evidence 
indicates that individuals do not exhibit a consistent 
relationship between MHPG and their moods. 
When correlations within each subject across the 
cycle were not significant, it was suspected on investi-
gation of means plotted across the cycle that the rela-
tionships between MHPG and the psychologicals would be 
different the first half of the cycle from the last half 
of the cycle. Correlations were computed with daily 
group means for days 6-11 and days 14-21 (Table 5). 
These days represented the two halves of the cycle. 
The results of these correlations were only suggestive 
since the number of days in each correlation was small, 
N = 6 and N = 7. Also many correlations were done which 
increased the chance of a type I error. 
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Same-day correlations produced low nonsignificant 
correlations except for a significant positive correlation 
for days 6-11 for the MHPG-negative affect correlation. 
This was regarded as inconclusive when compared to the 
trends suggested by the time-lagged correlations. 
When MHPG levels were time-lagged one day behind 
the psychological measures, the correlation coefficients 
increased. For days 6-11 they were positive; for days 
14-21 they were negative. On days 6-11, the positive 
correlation between MHPG and MDQ total was significant. 
On days 14-21, the negative correlation between MHPG and 
MDQ negative affect was significant. The associations 
between MHPG and the affective measures were different 
depending on phase of cycle as had been suggested in 
Figure 1. It cannot be argued, however, that the nature 
of the affect is different at ovulation and premenses. 
All the psychological variables show peaks at ovulation 
and premenses. This suggests a similar reaction to 
ovulation and to the onset of menses. In addition, all 
the MDQ factors maintain a consistent percentage of the 
MDQ total throughout the cycle. The explanation might 
be that both are correlated to another biochemical 
variable which also undergoes phasic changes, or per-
haps these psychological measures do not differentiate 
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an individual •s experience at ovulation and at premenses. 
The psychological variables were also time-lagged 
one day behind MHPG. These correlations between MHPG and 
the psychological variables were generally positive for 
days 6-11 and days 14-21. Only the state-anxiety corre-
lations 'produced a negative correlation for days 6-11. 
When MHPG levels were correlated with negative affect, 
a significant positive relationship was found at days 
14-21. When MHPG was correlated with MDQ total at days 
14-21, the r was also positive and significant. These 
correlations suggest that an increase in MHPG would be 
followed within a day with an increase in negative affect 
and menstrual distress. One earlier study of a manic-
depressive indicated that MHPG levels began to increase 
before a switch to mania (Deleon-Janes et al ., 1975). 
This might also indicate a time-lag of affective change 
behind a change in MHPG level. If after further investi-
gation this positive association between MHPG levels and 
negative affect is substantiated, the theory that 
depression increases as MHPG levels decrease would be 
open to question. 
Both methods of time-lagging suggested a 
possible relationship between MHPG changes and affec-
tive changes. With MHPG behind the psychological, it 
was suggested that the relationship was contingent on 
the subjects• psychological reaction to the phase of the 
menstrual cycle. When the psychological measures were 
lagged behind MHPG, a positive correlation was noted, 
especially with negative affect independent of the phase 
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of cycle. These different results highlight the complexity 
of the relationship of biochemical factors with psycho-
logical factors. With present methods, it seems diffi-
cult to unravel these complexities. 
Also to investigate the relationship of MHPG with 
the psychological measure at the various phases of the 
cycle, Pearson product-moment correlations were computed 
with means at each phase. All these correlations were 
nonsignificant. (Table 3) It was noted, however~ when 
plotting means for each phase, that women having phase 
means of MHPG above 1700 ~g per 24 hours displayed a 
different relationship with state-anxiety than those 
women with phase means below 1700 ~g. When the group 
was divided into low and high excreters at each phase, 
correlation coefficients increased. For low excreters 
there was a significant negative correlation for state-
anxiety at ovulation. There was also a significant 
positive correlation at premenses. High excreters produced 
correlation coefficients which were in the reverse 
direction or extremely low. These findings suggest that 
the relationship between state-anxiety and MHPG levels 
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is different for low and high excreters during the 
menstrual cycle. Level of MHPG excretion appears to be 
more closely associated to anxiety level in low excreters. 
The nature of this difference is not clear from 
this study and warrants further investigation since the 
number of subjects was small. Also when a continuously 
high excreter and a continuously low excreter were com-
pared, their correlations did not show the same direc-
tions as the group correlations for high and low excreters. 
This would also suggest the need for further study on 
excretion levels to verify the differences between high 
and low excreters suggested in this study. 
Other studies with depressives also indicate 
that high and low excretion levels are associated with 
different responses, in particular, responses to drug 
treatments. Low baseling MHPG excreters responded to 
imipramine and showed increases in MHPG levels after 
treatment. High MHPG excreters responded to amitryptyline 
and showed decreases in MHPG after treatment (Fawcett 
et al., 1972; Beckman et al., 1975; Mass, 1975). 
For STAI state-anxiety, Sweeney et al. (1978) 
found that those who showed increases in anxiety and in 
MHPG during an activity or a restricted activity 
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treatment had a lower baseline MHPG. Those with higher 
levels of MHPG showed decreases during the activity period. 
Therefore there is some earlier evidence which suggests 
that excretion level as such rather than diagnosis is 
associated with various patterns of affective response. 
Hence an individual would not show a significant correla-
tion between MHPG and mood. 
In conclusion, correlations between urinary MHPG 
levels and the psychological variables indicated that the 
relationships are not simple linear relationships. A num-
ber of intervening variables may exist. First, both MHPG 
and the psychological variables may be related to another 
biochemical variable which fluctuates during the menstrual 
cycle. Second, there was a large amount of individual 
variation in both psychological responses and MHPG excre-
tion levels during the cycle. Third, the relationship 
between MHPG and the psychological variables may change 
depending upon the time of the cycle. Fourth, there might 
be a time-lag between MHPG and the psychological variables. 
Fifth, the interaction between affect and MHPG may be dif-
ferent depending on the existing MHPG level. And finally 
there were methodological limitations in this study because 
of the magnitude of other possible intervening variables 
such as psychological stress from sources other than the 
menstrual cycle or from other biochemical factors. All 
these factors should be taken into account in future 
studies of MHPG levels in relation to affective variables. 
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Conclusions 
1. Increases in MHPG, the major brain metabolite of 
NE, at ovulation and at the late luteal phase support the 
hypothesis that neurotransmitters, in this case NE, are 
involved in the changes during the menstrual cycle within 
the hypothalamic-pituitary-ovarian system in women. 
2. Increases in anxiety and "menstrual distress 11 at 
premenses support the popular theory that many women 
experience a "premenstrual syndrome"--more tension, 
irritability, negative mood, and water retention prior to 
the onset of menses. Increases in anxiety and menstrual 
distress at ovulation suggest that ovulation can also be 
a time of stress for many women. None of these increases 
in the psychological variables, approach pathological 
levels when compared with normative data. 
3. Affective changes during the menstrual cycle are 
related to changes in MHPG in a complex way. The relation-
ship might depend on the phase of cycle, time-lagging of 
the psychological and biochemical variables, and the 
existing MHPG excretion level. These parameters reflect 
the intricacy of relating any psychological variable to a 
biochemical variable. 
4. The catecholamine hypothesis did not find support. 
No direct linear relationship was found between MHPG and 
negative affect and anxiety as measured with standardized 
scales. Repeated measures were taken for 23 days with no 
drug treatment. It was suggested that a cut-off of 
1700 ~g per 24 hours differentiated two excretion levels 
which are related to different patterns of affective 
reaction. It was suggested also that negative affect 
and anxiety increase as MHPG levels increase. More 
measures of spontaneous MHPG excretion and psychological 
self-reports would help clarify whether MHPG .levels are 
actually lower with increased depressive mood or whether 
that only applies to an individual with a clinical 
diagnosis of depression. 
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A number of suggestions for further research on 
the menstrual cycle arise from this study. Since there 
were 11 women with no depressive symptoms in this study, 
a comparison with women who experience depression could 
assist in determining whether depressive women experience 
more acute symptoms at ovulation and premenses than non-
depressive women. Also a standardized measure of daily 
events and their associated stress levels could be an 
additional measure for clarifying the high degree of 
individual variation in mood during the cycle. 
Methods which were effective in this study and 
warrant repetition were: (l) the use of daily self-reports 
to avoid cultural stereotypy about the menstrual cycle 
and (2) the accurate determination of ovulation which i·s 
absolutely essential when comparing differences across 
phases of the cycle. 
Mood changes and variation in MHPG levels were 
statistically supported in this study of 11 women. 
As in all research using group statistics~ however, it 
must be emphasized that there is individual variation. 
Also these statistically significant differences are not 
necessarily noticeable or substantial in everyday life. 
These qualifications are especially important when con-
ducting menstrual cycle research because of its impact 
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on the current re-evaluation of women's roles in society. 
SUMMARY 
Daily 24-hour urine collections were taken in 
order to measure MHPG, the major brain metabolite of NE, 
during one menstrual cycle of 11 normal free-cycling 
women. The psychological variables of state-anxiety 
(Spielberger et al., 1970), MDQ total, a measure of men-
strual distress, MDQ negative affect, and MDQ arousal 
(Moos, 1977) were assessed daily. The purpose of this 
research were (a) to assess the role of NE by means of 
MHPG levels in the human reproductive cycle, (b) to 
assess fluctuation in mood often attributed to bio-
chemical changes during the menstrual cycle, (c) to 
relate MHPG levels to psychological variables as was 
suggested by the catecholamine hypothesis of affective 
disorders. 
Trend analysis indicated that MHPG levels peaked 
at ovulation and the late-luteal phases. State-anxiety 
and MDQ total peaked at ovulation and premenses. Pearson 
product-moment correlations indicated that there were no 
direct linear relationships between MHPG and the psycho-
logical variables within individuals. Other Pearson 
product-moment correlations indicated that phase of cycle, 
level of MHPG excretion, and a time-lag effect may be 
intervening variables within the MHPG-mood relationship. 
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The following conclusions were drawn from this 
study: (l) fluctuations in MHPG during the cycle indicate 
the involvement of the neurotransmitter NE in the human 
reproductive cycle; (2) women experienced heightened 
anxiety and menstrual distress at ovulation and premenses 
which is within a normal range; (3) low MHPG levels are 
not directly related to an increase in depressive mood 
which would be expected according to the catecholamine 
hypothesis of affective disorder. In fact, the relation-
ship between MHPG levels and mood appears to be quite 
complex. 
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Day ~1HPG WR NA AR TOT ST-A p co BC 
01 1640 09 08 11 058 21 06 08 05 
02 1506 08 10 06 058 34 06 10 05 
03 1874 09 11 11 068 37 06 15 05 
04 2108 08 10 15 063 38 06 08 05 
05 1664 09 08 13 064 36 06 12 05 
06 1930 08 09 15 066 38 06 12 05 
07 2410 07 14 17 071 46 06 11 05 






14 1901 08 09 13 062 31 08 08 05 
15 2107 09 08 11 060 39 06 10 05 
16 2035 10 16 16 089 41 08 14 08 
17 1394 11 08 14 090 29 18 14 13 
18 1756 12 10 20 084 40 06 13 05 
19 1967 09 08 16 063 22 06 08 05 
20 2112 09 08 14 064 22 06 08 08 
21 1063 11 08 17 073 35 09 12 05 
22 1505 09 08 11 058 22 06 08 05 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1g1ycol=MHPG; 
water retention=WR; negative affect=NA; arousal=AR; 
total=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 





















Day MHPG WR NA AR TOT ST-A p co BC 
01 1950 04 11 12 075 32 21 08 05 
02 1724 04 11 14 071 30 15 08 08 
03 1438 06 15 13 088 30 21 15 07 
04 2104 04 10 14 063 32 11 08 05 
05 1986 07 09 11 075 32 17 12 07 
06 2403 05 25 12 093 46 15 16 09 
07 1888 04 11 13 077 42 19 12 06 
08 1927 05 11 12 073 28 20 08 05 
09 2314 06 10 17 070 34 10 10 06 
10 1647 04 09 14 074 32 20 11 05 
11 2626 13 09 15 086 30 19 11 06 
12 2138 09 18 09 080 49 19 14 07 
13 1479 04 13 16 073 23 11 10 08 
14 1983 07 11 12 077 30 16 11 07 
15 1954 05 14 15 070 37 10 09 06 
16 2228 09 ll 15 075 31 16 08 05 
17 2016 06 09 14 064 34 11 08 05 
18 2100 12 16 13 090 31 14 16 08 
19 1125 06 12 13 085 33 22 13 05 
20 2447 07 13 10 075 33 15 12 07 
21 1362 05 17 13 074 34 14 08 06 
22 1527 04 12 16 065 34 09 08 05 
23 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1g1ycol=MHGP; 
water retention=WR; negative affect=NA; arousal=AR; 
total=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 


























Day MHPG WR NA AR TOT ST-A p co BC 
01 1121 04 09 09 057 35 09 08 07 
02 1272 04 08 09 052 30 06 09 05 
03 1713 04 08 14 056 32 06 08 05 
04 0915 04 14 06 057 44 09 10 05 
05 1697 04 13 06 068 51 08 12 10 
06 1807 06 08 13 057 30 06 08 05 
07 1249 06 08 10 057 31 06 08 05 
08 1604 06 08 12 056 31 06 08 05 
09 0657 05 08 09 056 31 07 11 05 
10 1096 05 08 07 051 32 10 08 05 
11 1123 05 08 08 053 41 08 08 05 
12 1354 05 10 09 054 51 06 08 05 
13 1176 05 08 09 053 31 07 08 05 
14 1272 06 08 10 056 33 08 08 05 
15 1414 06 10 08 058 35 08 10 05 
16 1254 06 10 08 057 36 08 08 05 
17 1237 08 08 09 060 32 09 08 05 
18 1119 08 13 06 073 42 16 08 08 
19 1044 06 09 07 067 37 13 10 11 
20 1225 08 08 12 059 31 07 08 05 
21 1394 06 08 10 056 30 07 09 05 
22 1810 06 08 08 057 30 11 08 05 
23 1450 06 09 08 057 31 09 08 06 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1g1yco1=MHPG; 
water retention=WR; negative affect=NA; arousal=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 



























Day MHPG WR NA AR TOT ST-A p co BC 
01 
02 0874 05 14 09 067 43 
03 0848 05 08 09 060 34 
04 
05 1140 04 09 10 061 36 10 10 07 
06 1150 04 14 08 066 30 09 10 10 
07 1115 04 08 16 067 24 08 08 08 
08 1082 06 14 09 064 48 07 09 04 
09 1096 08 08 11 062 29 10 08 05 
10 0971 08 13 11 069 41 09 08 09 
ll 0997 08 14 08 079 48 10 16 10 
12 1135 05 14 09 065 48 10 09 07 
13 1148 08 09 12 067 39 09 ll 07 
14 1057 10 09 10 063 32 07 08 06 
15 1175 07 13 065 46 08 11 06 
16 0927 ll 13 11 072 42 10 08 07 
17 1071 11 14 09 082 55 11 16 09 
18 0850 12 09 14 092 34 10 21 13 
19 09 19 12 
20 1595 09 08 15 084 32 08 10 05 
21 1656 10 08 10 062 30 15 08 05 
22 1016 07 11 11 068 38 08 10 07 
23 1261 04 10 10 056 42 12 08 05 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1glycol=MHPG; 
water retention=WR; negative affect=NA; arousal=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 























Day MHPG WR NA AR TOT ST-A p co BC 
01 1275 06 19 12 108 63 16 24 16 
02 1354 09 16 17 103 40 15 20 10 
03 1149 08 14 14 092 44 12 21 09 
04 1058 07 13 14 086 33 14 20 09 
05 1786 11 11 18 089 37 10 19 07 
06 2232 11 11 15 082 33 10 14 05 
07 2021 10 15 15 085 36 10 13 06 






"14 1783 11 10 14 083 35 16 12 07 
15 2185 11 10 14 090 30 14 17 10 
16 1909 09 12 17 076 33 09 10 07 
17 1960 08 14 15 076 42 09 10 06 
18 2187 06 25 10 084 59 09 10 12 
19 2130 08 17 10 103 55 15 17 21 
20 2305 08 13 15 082 41 10 11 14 
21 2121 07 11 15 076 50 11 13 06 
22 1555 08 12 15 079 40 11 10 08 
23 
NOTE: Abbreviated 3 methoxy-4-hydroxyphenylglycol=MHPG; 
water retention=WR; negative affect=NA; arousa1=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 





















Day MHPG WR NA AR TOT ST-A p co BC 
01 1356 04 10 07 052 39 07 08 05 
02 2062 04 10 08 053 39 07 08 05 
03 2072 04 08 09 051 39 06 08 05 
04 1401 04 09 07 052 35 07 08 06 
05 
06 1905 04 08 06 051 46 06 11 05 
07 2168 05 10 07 054 43 07 08 06 
08 2245 04 09 09 053 41 07 08 05 
09 1767 04 08 08 052 36 06 10 05 
10 1861 04 10 07 052 37 07 08 05 
11 1509 04 08 07 050 39 07 08 05 
12 1819 04 08 06 049 39 07 08 05 
13 1141 04 08 08 050 46 06 08 05 
14 2164 04 08 07 053 48 06 12 05 
15 2008 04 12 08 056 48 07 08 05 
16 2188 07 09 05 059 41 10 11 06 
17 1910 09 12 06 064 41 l3 08 05 
18 1935 08 11 06 066 46 12 09 06 
19 1849 07 08 06 058 36 12 08 06 
20 1901 07 09 08 062 25 11 08 06 
21 1680 04 08 07 061 39 12 08 06 
22 1881 06 09 07 056 41 09 08 06 
23 2214 05 08 07 056 36 11 09 05 
NOTE: Abbreviated 3 methoxy-4-hydroxyphenylg1ycol=MHPG; 
water retention=WR; negative affect=NA; arousal=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 


























Day MHPG WR NA AR TOT ST-A p co BC 
01 0987 06 15 09 075 34 17 10 06 
02 1283 05 28 10 081 40 13 09 05 
03 0577 07 25 08 080 60 10 12 07 
04 1101 06 11 16 064 37 06 08 06 
05 1025 05 14 16 069 31 10 08 05 
06 1444 05 16 16 074 44 09 10 06 
07 1251 07 17 15 073 33 08 11 05 
08 1486 07 22 11 077 35 08 11 05 
09 0888 04 14 10 065 41 06 10 05 
10 07 09 05 
11 0486 07 11 11 061 30 09 14 05 
12 0586 05 20 13 077 33 11 10 06 
13 0927 07 21 14 081 33 
14 1117 06 13 14 070 31 13 08 05 
15 1196 08 14 11 067 46 10 08 05 
16 0946 13 16 08 070 49 07 09 06 
17 0842 10 12 12 066 44 08 08 05 
18 1384 05 17 10 071 36 12 11 05 
19 0923 09 08 11 063 28 11 08 05 
20 09 11 05 
21 1274 10 12 16 077 32 10 08 05 
22 0877 05 16 12 070 32 10 09 05 
23 1234 04 14 10 067 30 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1g1yco1=MHPG; 
water retention=WR; negative affect=NA; arousa1=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 

























Day MHPG WR NA AR TOT ST-A p co BC 
01 0750 04 10 16 065 39 
02 0665 04 08 18 062 22 08 08 05 
03 0741 04 08 17 061 21 08 08 05 
04 0661 04 08 16 052 24 06 08 05 
05 0556 05 10 19 066 34 08 08 05 
06 0742 04 13 05 113 51 24 13 29 
07 0714 04 26 10 101 67 20 17 09 




12 0801 04 08 20 062 26 06 08 05 
13 0868 05 12 16 071 32 12 10 05 
14 0851 05 08 17 062 24 08 08 05 
15 1382 04 08 19 063 24 08 08 05 
16 1282 
17 1293 09 24 10 096 65 19 12 07 
18 1121 05 08 17 063 21 08 08 05 
19 0917 05 08 18 061 20 06 08 05 
20 0953 06 18 08 089 40 20 09 14 
21 11 08 07 
22 0795 05 09 14 065 37 
23 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1g1yco1=MHPG; 
water retention=WR; negative affect=NA; arousa1=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 




















Day MHPG WR NA AR TOT ST-A p co BC 
01 1286 04 08 05 047 29 06 08 05 
02 1113 04 10 08 055 22 06 08 08 
03 1329 04 14 10 063 37 11 08 05 
04 1008 04 10 09 060 28 13 08 05 
05 1132 04 21 10 074 42 09 10 09 
06 2583 04 14 11 062 34 08 08 05 
07 1437 04 11 08 063 32 12 08 09 
08 1898 06 10 08 063 31 11 10 07 
09 10 13 09 
10 08 13 05 
11 1289 07 08 10 068 28 09 08 07 
12 2236 09 10 06 062 36 
13 1809 09 08 08 060 32 
14 2081 08 14 08 062 27 07 08 07 
15 1930 06 13 10 060 32 06 08 07 
16 1747 10 12 08 067 25 06 08 06 
17 1749 13 08 11 068 37 10 11 05 
18 0974 07 25 10 082 47 07 08 06 
19 1122 06 22 08 088 38 10 11 08 
20 1462 04 29 12 085 29 14 12 15 
21 1490 05 24 09 071 41 11 11 07 
22 1347 07 21 12 078 32 09 08 05 
23 1406 04 14 10 060 36 06 09 06 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1glycol=MHPG; 
water retention=WR; negative affect=NA; arousal=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 

























Day MHPG WR NA AR TOT ST-A p co BC 
01 1685 06 09 13 078 33 13 13 07 
02 1178 07 10 15 076 35 09 12 07 
03 1406 07 12 14 081 34 11 12 08 
04 1477 07 12 15 081 33 09 11 08 
05 1298 
06 1526 07 10 16 31 09 14 07 
07 0952 07 12 15 33 09 12 09 
08 1780 06 12 15 31 08 08 10 
09 0924 10 11 18 096 35 17 l7 08 
10 1621 09 12 16 087 27 16 14 07 
11 1236 08 10 15 081 36 14 11 08 
12 1011 11 15 17 096 36 13 12 16 
13 1232 29 14 12 09 
14 2073 09 17 15 102 30 16 13 10 
15 1175 08 12 14 084 34 11 13 05 
16 1807 11 15 18 096 43 13 12 08 
17 0844 09 12 16 088 37 12 14 06 
18 2100 10 12 15 083 41 08 13 08 
19 1182 08 12 14 088 33 13 12 07 
20 0978 07 11 14 083 32 11 12 08 
21 1407 11 09 14 085 31 13 11 09 
22 
23 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1glycol=MHPG; 
water retention=WR; negative affect=NA; arousal=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 
























Day MHPG WR NA AR TOT ST-A p co BC 
01 1346 04 14 19 079 28 06 11 05 
02 1586 04 08 08 063 26 08 11 07 
03 1557 04 08 10 060 34 08 08 07 
04 2173 04 14 14 079 26 12 09 09 
05 1967 04 17 21 082 25 06 11 05 
06 1703 04 13 16 076 28 10 08 07 
07 2333 05 10 13 085 27 18 08 10 
08 1263 05 08 12 066 27 10 11 05 
09 1533 05 10 21 077 25 06 12 07 
10 1623 04 17 14 081 41 11 08 07 
11 1196 04 19 13 090 46 11 14 08 
12 
13 
14 2571 04 08 09 066 22 07 13 10 
15 1324 04 11 07 072 44 12 10 07 
16 2416 04 11 09 063 34 07 08 09 
17 1527 04 11 13 069 37 11 08 05 
18 1679 05 12 08 070 39 11 12 05 
19 1541 07 15 09 073 31 10 13 07 
20 1617 06 14 14 077 41 11 10 08 
21 1094 05 16 10 081 30 12 14 07 
22 05 11 14 068 22 07 08 07 
23 1457 04 35 14 100 30 13 14 05 
NOTE: Abbreviated 3 methoxy-4-hydroxypheny1g1ycol=MHPG; 
water retention=WR; negative affect=NA; arousa1=AR; 
tota1=TOT; state-anxiety=ST-A; pain=P; concentration=CO; 
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